Shield Therapeutics has raised funds

Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.

Shield is a de-risked, specialty pharmaceutical company focused on commercializing its lead product, Feraccru®/Accrufer®, a novel, non-salt-based oral therapy for adults with iron deficiency with or without anemia.

Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as the joint broker on this transaction.

SERVICIO

Financiamiento, deuda y mercados de capitales

PARTES

Contáctese con el equipo de la transacción

Geoff Nash

Director

Londres, Reino Unido
Oaklins Cavendish

Ver perfil Contáctenos

Transacciones relacionadas

AMC Media Group has been acquired by Formedics

Salud | TMT

AMC Media Group has been acquired by Formedics

AMC Media Group, a health care professional (HCP) community platform that enables medical associations and key opinion leaders (KOLs) to drive engagement and monetization through their specialty digital properties, has been acquired by Formedics, an HCP community and engagement platform that is home to Physician's Weekly and OncWeekly.

Bellefleur has been acquired by Domidep

Salud

Bellefleur has been acquired by Domidep

Belgian nursing home Bellefleur has been sold to Domidep, one of France’s largest private nursing home operators.

Unitary Healthcare has been acquired by Axel Health

Private Equity | Salud | TMT

Unitary Healthcare has been acquired by Axel Health

Axel Health Oy, headquartered in Finland, has acquired the Finnish software company Unitary Healthcare Oy.